N-(3-Carboxy-propionyl)-L-asparaginsaeure | 4432-57-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-Carboxy-propionyl)-L-asparaginsaeure
• 英文别名: 2-(3-carboxy-propionylamino)-succinic acid；N-Succinyl aspartic acid；(2S)-2-(3-carboxypropanoylamino)butanedioic acid
• CAS: 4432-57-9
• 化学式: C₈H₁₁NO₇
• 分子量: 233.178
• InChiKey: YTMGDVQAVPGKLG-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  141
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-(3-Benzyloxycarbonyl-propionyl)-L-asparaginsaeure-dibenzylester 在 palladium on activated charcoal 氢气 作用下， 生成 N-(3-Carboxy-propionyl)-L-asparaginsaeure
  参考文献：
  名称：

  脂肪酸和谷氨酸的一些衍生物。

  摘要：

  DOI：

  10.1002/jps.2600520907

文献信息

• Synthesis and in vitro evaluation of aspartate transcarbamoylase inhibitors
  作者：Laëtitia Coudray、Anne F. Pennebaker、Jean-Luc Montchamp

  DOI：10.1016/j.bmc.2009.09.045

  日期：2009.11

  phosphorus-containing inhibitors are described, but all-carboxylate compounds are inactive. Compounds were synthesized to probe the postulated cyclic transition-state of the enzyme-catalyzed reaction. In addition, the associated role of the protonation state at the phosphorus acid moiety was evaluated using phosphinic and carboxylic acids. Although none of the synthesized inhibitors is more potent than N-pho

  报道了一系列新型天冬氨酸转氨甲酰酶（ATCase）抑制剂的设计、合成和评估。描述了几种亚微摩尔含磷抑制剂，但全羧酸盐化合物均无活性。合成化合物以探测酶催化反应的假定循环过渡态。此外，使用次膦酸和羧酸评估了含磷酸部分的质子化状态的相关作用。尽管合成的抑制剂均不比N-膦酰基-L-天冬氨酸 (PALA) 更有效，但这些化合物提供了有用的机制信息，以及未来抑制剂和/或前药设计的基础。
• Chemosensory Receptor Ligand-Based Therapies
  申请人：Brown Martin R.

  公开号：US20130303466A1

  公开（公告）日：2013-11-14

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
• [EN] CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES<br/>[FR] THÉRAPIES À BASE DE LIGAND DE RÉCEPTEUR CHIMIOSENSIBLE
  申请人：ELCELYX THERAPEUTICS INC

  公开号：WO2012054527A2

  公开（公告）日：2012-04-26

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.